Legal & General Group Plc Purchases 25,219 Shares of Zimmer Biomet Holdings, Inc. $ZBH

Legal & General Group Plc boosted its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 1.7% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,534,016 shares of the medical equipment provider’s stock after acquiring an additional 25,219 shares during the period. Legal & General Group Plc’s holdings in Zimmer Biomet were worth $137,939,000 as of its most recent filing with the SEC.

Several other hedge funds have also added to or reduced their stakes in ZBH. Key Financial Inc raised its position in Zimmer Biomet by 164.6% in the third quarter. Key Financial Inc now owns 262 shares of the medical equipment provider’s stock worth $26,000 after acquiring an additional 163 shares during the period. Cullen Frost Bankers Inc. raised its position in Zimmer Biomet by 66.7% in the third quarter. Cullen Frost Bankers Inc. now owns 290 shares of the medical equipment provider’s stock worth $29,000 after acquiring an additional 116 shares during the period. Flagship Harbor Advisors LLC bought a new stake in Zimmer Biomet in the fourth quarter worth about $32,000. Grove Bank & Trust raised its position in Zimmer Biomet by 431.6% in the fourth quarter. Grove Bank & Trust now owns 404 shares of the medical equipment provider’s stock worth $36,000 after acquiring an additional 328 shares during the period. Finally, Headlands Technologies LLC bought a new stake in Zimmer Biomet in the second quarter worth about $37,000. Institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Price Performance

Shares of NYSE:ZBH opened at $82.92 on Friday. The company has a 50 day moving average of $88.09 and a 200 day moving average of $90.69. The stock has a market cap of $16.04 billion, a P/E ratio of 21.54, a P/E/G ratio of 1.91 and a beta of 0.48. Zimmer Biomet Holdings, Inc. has a 12 month low of $79.12 and a 12 month high of $108.29. The company has a current ratio of 1.73, a quick ratio of 0.95 and a debt-to-equity ratio of 0.50.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings data on Tuesday, April 28th. The medical equipment provider reported $2.09 EPS for the quarter, beating the consensus estimate of $1.86 by $0.23. The company had revenue of $2.09 billion during the quarter, compared to analysts’ expectations of $2.07 billion. Zimmer Biomet had a net margin of 9.05% and a return on equity of 13.24%. Zimmer Biomet’s revenue for the quarter was up 9.3% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.81 earnings per share. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. As a group, sell-side analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.47 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Thursday, June 25th will be paid a dividend of $0.24 per share. The ex-dividend date of this dividend is Thursday, June 25th. This represents a $0.96 annualized dividend and a yield of 1.2%. Zimmer Biomet’s payout ratio is currently 24.94%.

Insider Buying and Selling

In related news, SVP Lori Winkler sold 2,650 shares of the business’s stock in a transaction that occurred on Thursday, March 12th. The shares were sold at an average price of $94.66, for a total transaction of $250,849.00. Following the completion of the transaction, the senior vice president owned 10,224 shares of the company’s stock, valued at approximately $967,803.84. The trade was a 20.58% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 1.28% of the company’s stock.

Analyst Ratings Changes

Several analysts have commented on the stock. Weiss Ratings raised shares of Zimmer Biomet from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Tuesday, April 7th. Barclays lowered their price objective on shares of Zimmer Biomet from $100.00 to $94.00 and set an “underweight” rating on the stock in a research report on Wednesday, April 29th. Wells Fargo & Company lowered their price objective on shares of Zimmer Biomet from $98.00 to $90.00 and set an “equal weight” rating on the stock in a research report on Wednesday, April 29th. BTIG Research reiterated a “neutral” rating on shares of Zimmer Biomet in a research note on Monday, March 23rd. Finally, William Blair started coverage on shares of Zimmer Biomet in a research note on Friday, February 20th. They issued a “market perform” rating for the company. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, twelve have issued a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $102.70.

Zimmer Biomet Company Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.